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Success in Secondary CV Prevention 
 
The combination of a new low dose of 2.5-mg twice-
daily rivaroxaban plus 100-mg once-daily aspirin was 
associated with a reduction in ischemic events and 
mortality and a superior net clinical benefit, balancing 
ischemic benefit with severe bleeding, than aspirin 
alone for secondary prevention in patients with stable 
atherosclerotic vascular disease in the COMPASS trial.  
 
  European Society of Cardiology (ESC) 2017 Congress  
http://www.medscape.com/viewarticle/884743 
William Heberden on Angina Pectoris, 1 
There is a disorder of the breast marked 
with strong and peculiar symptoms, 
considerable for the kind of danger 
belonging to it, and not extremely rare, 
which deserves to be mentioned more 
at length. The seat of it and the sense of 
strangling and anxiety with which it is 
attended, may make it not improperly be 
called angina pectoris.   
Heberden, W. 1772. Some account of a 
disorder of the breast. 
 
epi.umn.edu/cvdepi/essay 
1772 
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dieselotherapy.tumblr.com/post/84365697545/brains-and-bodies-what-is-coronary-heart-disease 
Definition 1  
Ischemic heart disease (IHD) or Coronary artery 
disease (CAD) is a group of diseases that 
characterized by impaired myocardial 
function due to decrease blood flow through 
the affected coronary arteries and includes silent 
ischemia, stable angina, unstable angina, 
myocardial infarction, and sudden cardiac death. 
Most IHD is caused by atherosclerotic vascular 
disease (ASVD), usually present even when the 
artery lumens appear normal by angiography. 
   en.wikipedia.org/wiki/Coronary_artery_disease 
Definition 2  
Stable forms of IHD (SIHD) include first two from 
the list SIHD cause narrowing of coronary 
arteries with chronic inadequate blood supply 
to the myocardium that can ultimately lead from 
silent ischemia to heart attacks with chest pain 
or discomfort known as stable angina pectoris 
most commonly experienced during physical 
and/or emotional distress. 
 
 en.wikipedia.org/wiki/Coronary_artery_disease 
Epidemiology   
(Coronary Artery Disease around the World ) 
nature.com/nrcardio/journal/v11/n5/full/nrcardio.2014.26.html 
The global distribution of ischaemic heart 
disease burden, in disability-adjusted life years 
(DALYs), in 2011. 
Epidemiology    
(Focus on Key Heart Diseases) 
The proportions of cardiovascular deaths (a) Men, (b) 
Women) caused by IHD, cerebrovascular disease, 
inflammatory heart disease, rheumatic heart disease, 
hypertensive heart disease, and other cardiovascular 
diseases in 2011.  
nature.com/nrcardio/journal/v11/n5/full/nrcardio.2014.26.html 
Risk Factors 
(Modifiable 1) 
en.wikipedia.org/wiki/Atherosclerosis 
• Diabetes or impaired glucose tolerance (IGT)   
• Dyslipoproteinemia: high serum concentration 
of low-density lipoprotein (LDL), and / or very 
low density lipoprotein (VLDL) particles; low 
serum concentration of functioning high 
density lipoprotein (HDL); an LDL:HDL ratio 
greater than 3:1 
• Tobacco smoking   
Risk Factors 
(Modifiable 2) 
en.wikipedia.org/wiki/Atherosclerosis 
• Tobacco smoking  
• Overweight and Obesity 
• Physical inactivity 
• Elevated serum C-reactive 
protein concentrations 
• Hypertension 
• Vitamin B6 deficiency 
• Dietary iodine deficiency and hypothyroidism  
Risk Factors 
(Nonmodifiable) 
en.wikipedia.org/wiki/Atherosclerosis 
• Advanced age 
• Male sex 
• Having close relatives who have had some 
complication of atherosclerosis (e.g. coronary 
heart disease or stroke) 
• Genetic abnormalities, e.g. familial 
hypercholesterolemia 
Risk Factors 
(Lesser or Uncertain 1) 
en.wikipedia.org/wiki/Atherosclerosis 
• Being of South Asian ethnicity   
• Hypercoagulability 
• Postmenopausal estrogen deficiency 
• High intake of saturated fat 
• Trans fat intake  
• High carbohydrate intake 
• Elevated serum levels of triglycerides 
• Elevated serum levels of homocysteine  
Risk Factors 
(Lesser or Uncertain 2) 
en.wikipedia.org/wiki/Atherosclerosis 
•  Elevated serum levels of uric acid  
• Elevated serum fibrinogen concentrations 
• Elevated serum lipoprotein concentrations 
• Chronic systemic inflammation  
• Elevated serum insulin levels  
• Short sleep duration 
• Chlamydia pneumoniae infection 
• Air pollution 
Risk Factors 
(Traditional versus Nontraditional Risk Factors) 
emedicine.medscape.com/article/164163-overview 
The expanding list of nontraditional 
biomarkers is outweighed by the 
standard risk factors for predicting 
future cardiovascular events and 
adds only moderately to standard 
risk factors. BNP = B-type 
natriuretic peptide; BP = blood 
pressure; CRP = C-reactive protein; 
HDL = high-density lipoprotein 
cholesterol; HIV = human 
immunodeficiency virus infection. 
Risk Factors 
(Factors That Have an Impact on the IHD Events’ Risk) 
content.onlinejacc.org/article.aspx?articleid=1140128 
Mechanisms   
(Key Moments 1)     
pathophys.org/acs/ 
• Chronic myocardial ischemia is a consequence 
of reduced blood flow in coronary arteries, due 
to a combination of fixed vessel 
narrowing and abnormal vascular tone as a 
result of ASVD and endothelial dysfunction with 
an imbalance between myocardial oxygen 
supply and demand:  
• The degree and the length of vessel 
narrowing affect the hemodynamic 
significance of a stenotic lesion  
Mechanisms   
(Key Moments 2)     
pathophys.org/acs/ 
• Endothelial dysfunction contributes to 
myocardial ischemia in inappropriate 
vasoconstriction of coronary arteries   
• Non-ASVD causes of myocardial ischemia 
include  decreased coronary perfusion pressure 
due to hypotension; decreased blood oxygen 
content due to marked anemia and pulmonary 
disease, unusual (e.g. congenital) coronary 
abnormalities, etc.   
Mechanisms   
(Myocardial Ischemia begets more Ischemia)     
onlinelibrary.wiley.com/doi/10.1002/clc.20048/pdf 
Factors Important in SIHD 
Mechanisms   
(miRNAs and their targets in Cardiac Ischemia)     
physrev.physiology.org/content/91/3/827 
The different miRNAs (posttranscriptional regulators) 
and their targets that are involved in cell viability, 
angiogenesis, fibrosis, and electrical remodeling 
during cardiac ischemia.  
Classification 
(International Classification of Diseases (ICD) 1) 
apps.who.int/classifications/icd10/browse/2016/en#/I20-I25 
Chapter IX 
Diseases of the circulatory system 
(I00-I99)  
I20-I25 Ischaemic heart diseases 
              I20.1 Angina pectoris with documented 
spasm 
                        Angina (angiospastic, Prinzmetal, 
spasm-induced, variant) 
              I20.8 Other forms of angina pectoris 
         Angina of effort  
Classification 
(International Classification of Diseases (ICD) 2) 
apps.who.int/classifications/icd10/browse/2016/en#/I20-I25 
  Coronary slow flow syndrome 
                        Stable angina 
                        Stenocardia 
              I20.9 Angina pectoris, unspecified 
         Angina ( NOS (not otherwise specified), 
cardiac) 
                        Anginal syndrome 
                        Ischaemic chest pain 
Classification 
(Canadian Cardiac Society Angina Class Scale (C CSA) 1)  
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
Classification 
(Canadian Cardiac Society Angina Class Scale (C CSA) 2)  
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
Classification 
(from Stable Angina until Accelerating Angina 1) 
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
• Angina is stable when its pattern of 
frequency, intensity, ease of provocation, or 
duration does not change over a period of 
several weeks. Identification of activities 
that provoke angina and the amount of 
sublingual nitroglycerin required to relieve 
symptoms are helpful indicators of stability 
versus progression.   
Classification 
(from Stable Angina until Accelerating Angina 2) 
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
• Angina is accelerating when there is a 
change in the pattern of stable angina. This 
may include a greater ease of provocation, 
more prolonged episodes, and episodes of 
greater severity, requiring a longer recovery 
period or more frequent use of sublingual 
nitroglycerin. This suggests a transition and 
most likely reflects a change in coronary 
artery blood flow and perfusion of the 
myocardium.   
Clinical Investigation  
(Passions around Symptoms 1) 
• Chest pain (angina) can be described as a 
heaviness, pressure, aching, burning, 
numbness, fullness, squeezing, discomfort or 
painful feeling in the chest, but may also be felt 
in the left shoulder, arms, neck, back, or jaw. 
• Shortness of breath. 
• Palpitations. 
• Weakness or dizziness.  
webmd.com 
Clinical Investigation  
(Passions around Symptoms 2) 
• Nausea. 
• Sweating. 
• Some patients have no signs or symptoms 
(silent ischemia) until there will be developed 
symptoms of a heart attack, heart failure, or 
an arrhythmia.   
webmd.com 
Clinical Investigation  
(Common Locations and Patterns of  Angina Pain) 
s3.amazonaws.com/classconnection/12/flashcards/9384012/png/angina-153389544C30E11EA69.png eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
The characteristics of discomfort-related to angina may be 
divided into four categories: location, character, duration and 
relationship to exertion and other exacerbating or relieving 
factors. The discomfort caused by myocardial ischemia is 
usually located in the chest, near the sternum, but may be felt 
anywhere from the epigastrium to the lower jaw or teeth, 
between the shoulder blades or in either arm to the fingers. 
Clinical Investigation  
(Traditional Clinical Classification of Chest Pain) 
Typical angina  
(definite) 
Meets all three of the following 
characteristics:  
• substernal chest discomfort of 
characteristic quality and duration;  
• provoked by exertion or emotional 
stress; • relieved by rest and/or nitrates 
within minutes. 
Atypical angina 
(probable)  
Meets two of these characteristics. 
Non-anginal 
chest pain  
Lacks or meets only one or none of the 
characteristics. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Clinical Investigation  
(Hallmark of Prinzmetal Angina 1) 
• In contrast to patient with stable angina 
secondary to coronary atherosclerosis, patients 
with Prinzmetal (variant) angina (until 10% of 
angina patients)  are younger and have fewer 
coronary risk factors (except smoking). 
• Episode of chest pain usually does not progress 
from a period of chronic stable angina.  
en.wikipedia.org/wiki/Prinzmetal%27s_angina 
Clinical Investigation  
(Hallmark of Prinzmetal Angina 2) 
• Cardiac examination is normal in the absence of 
ischemia. 
• Symptoms occur at rest (usually at night), rather 
than on exertion.  
• 2/3 of patients have 
concurrent atherosclerosis of a major coronary 
artery, but this is often mild or not in proportion 
to the degree of symptoms.  
en.wikipedia.org/wiki/Prinzmetal%27s_angina 
Clinical Investigation  
(Passions around Cardiac Syndrome X: 1) 
• Cardiac syndrome X is angina associated with 
decreased blood flow to the heart tissue with 
normal coronary arteries and referred to 
microvascular dysfunction. 
• Angina is most of the time unpredictable and it 
can occur when at rest and/or during exercise.  
• Pain is normally more intense and it lasts for 
longer periods of time compared to pain caused 
by other conditions.   
en.wikipedia.org/wiki/Cardiac_syndrome_X 
Clinical Investigation  
(Passions around Cardiac Syndrome X: 2) 
• Some studies have found increased risk of other 
vasospastic disorders, such as 
migraine and Raynaud's phenomenon.  
• It is treated with beta-blockers and usually 
carries a favorable prognosis. 
• This is a distinct diagnosis from Prinzmetal 
angina. 
en.wikipedia.org/wiki/Cardiac_syndrome_X 
Clinical Investigation  
(Stable Angina versus Myocardial Infarction Comparison Chart) 
diffen.com/difference/Myocardial_Infarction_vs_Stable_Angina 
Symptoms Myocardial Infarction Stable Angina 
Occurrence of 
pain 
Occurs at any time Occurs due to physical  or 
emotional stress 
Modality of 
pain 
With damage to the heart 
and described as severe, 
steady, and crushing  
With no damage to the heart   
Outcome May be fatal Usually not fatal 
Relieving 
factors of pain 
Symptoms persists after 
15 min. and not relieved 
by rest or nitro  
Symptoms relieved by rest or 
nitro within 10-15 min.  
Duration of 
pain 
Usually lasts for more 
than 15 min. 
Usually for less than 15 min. 
Serum cardiac 
marker 
Present Not present 
Clinical Investigation  
(History 1) 
• The history should include any current symptoms 
and a complete inventory of comorbid conditions.  
• An inventory of cardiac risk factors, and a complete 
family history are essential components.  
• The history should also include information about 
the character and location of discomfort, radiation 
of discomfort, associated symptoms, and 
precipitating, exacerbating, or alleviating factors.   
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
Clinical Investigation  
(History 2) 
• The importance of the family history should not be 
underestimated.  
• A detailed assessment, particularly of first-degree 
relatives for the presence of IHD and age of 
diagnosis is imperative when evaluating a patient's 
risk factor profile. 
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
Clinical Investigation  
(Physical Examination 1) 
• The results of the physical examination of a 
patient may be entirely normal.  
• The presence of multiple risk factors or 
atherosclerosis in the carotid or peripheral 
arteries increases the likelihood that a chest 
pain syndrome is related to myocardial 
ischemia.  
• Evaluation should include measurements of 
blood pressure and the ankle-brachial index.  
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
Clinical Investigation  
(Physical Examination 2) 
• Examination of the carotid arteries should include 
auscultation for bruits.  
• Examination of the chest wall, neck, and 
shoulders for deformities and tenderness may be 
helpful in diagnosing musculoskeletal chest 
discomfort.  
• Cardiac auscultation may detect murmurs caused 
by aortic stenosis or hypertrophic 
cardiomyopathy, either of which can cause angina 
in the absence of IHD.  
 
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
Clinical Investigation  
(Physical Examination 3) 
• Assessment of the abdominal aorta for an 
aneurysm or bruits and palpation of lower 
extremity pulses is necessary to evaluate for 
peripheral vascular disease.  
• Careful palpation of all peripheral pulses and 
assessment of symmetry versus diminution are 
also valuable noninvasive approaches for assessing 
the integrity of the arterial circulation.  
• Finally, examination for xanthelasmas, tendon 
xanthomas, retinal arterial abnormalities, and 
peripheral neuropathy can be helpful. 
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
Diagnosis 1 
  
• Electrocardiogram (ECG): reveal  evidence of a 
previous heart attacks 
• B-mode, Doppler and intravascular ultrasound: 
degree of any blockages in arteries 
• Ankle-brachial index: recognition of peripheral 
vascular disease, which is usually caused by 
atherosclerosis 
• Stress test (including echocardiogram): 
reveal  evidence of a chronic coronary artery 
disease  
en.wikipedia.org/wiki/Coronary_artery_disease#Diagnosis 
Diagnosis 2 
  
• Ambulatory ECG 
•  Vascular catheterization and angiogram: 
reveal  evidence of narrowed, blocked or 
aneurismatic arteries 
• Other imaging tests (CT, MRA, etc.): 
reveal  evidence of narrowed or blocked arteries, 
as well as aneurysms and calcium deposits in the 
artery walls 
• Blood tests: cholesterol and C-reactive protein 
levels, lipoproteinogram  
 en.wikipedia.org/wiki/Coronary_artery_disease#Diagnosis 
USMLE STEP 2  
A 67-year-old male with a history of prior myocardial infarction 
and catherization-confirmed coronary heart disease presents to 
his cardiologist. He notes that he has had increased chest pain 
on exertion for the past 2 months. He also reports two episodes 
of chest pain at rest in the past month. His current medications 
include carvedilol daily and nitroglycerin as needed. The 
cardiologist orders a cardiac stress test to be performed as an 
outpatient. Which of the following advice should the patient be 
given regarding preparation for the test? 
1.  Do not take carvedilol and nitroglycerin for 1 day prior to the 
test, 2.  Do not take carvedilol and nitroglycerin for 4 days prior 
to the test, 3.  Take carvedilol alone on the day prior to the test,  
4.  Take nitroglycerin alone on the day prior to the test, 
5.  Continue to take carvedilol and nitroglycerin as instructed  
USMLE STEP 2   
Correct answer 5:  Patients with known coronary artery 
disease (CAD) should not withhold antianginal 
medications (carvedilol and nitroglycerin) prior to a 
cardiac stress test. 
Incorrect Answers: 
1: Patients with no known history of CAD should withhold 
antianginal medications for 24-48 hours prior to cardiac 
stress testing. However, this patient has a known history 
of CAD. 
2-4: In this patient with known CAD, all antianginal 
medications should be continued through the time of the 
stress test, as the results will indicate whether the current 
medication regiment if effective during exercise.  
Diagnosis 
(Electrocardiogram)  
An old post-infarction scar of the front wall (deep Q in V1- 
V4). The situation is most probably complicated by a 
suspected ventricular aneurysm. ST sections for QRS in V1 -V4 
are elevated, best seen in V4 where the elevation reminds the 
Pardee’s wave (underlined in red). 
health-tutor.com/myocardial-scar-ecg.html 
Diagnosis 
(Ultrasound)  
Images of the left main (LMCA) and proximal the left anterior 
descending coronary artery (LAD - pLAD). The left parasternal 
position, a modified parasternal short axis view of great 
vessels.A – LMCA, B-mode; B – pLAD, B-mode; C – LMCA, 
Color Doppler mapping; D - bifurcation of the LMCA.   
health-tutor.com/myocardial-scar-ecg.html 
Diagnosis 
(Stress test)  
54-year-old male, with a chest pain during exercise (II C CSA) 
underwent an exercise stress test. ECG demonstrated  an 
increase in R wave amplitude from V1 to V4, and minor ST 
segment depression in DII, DIII and aVF.  Coronary angiogram 
showed a critical proximal left anterior descending artery 
lesion. cogprints.org/4806/1/uchida.htm 
Diagnosis 
(Ambulatory ECG)  
Prinzmetal angina. A. Control. Lead II 
(top), precordial lead (bottom). B. 
Marked ST-segment elevation, 
associated with mild angina. C. High-
grade atrioventricular block and 
continued ST-segment elevation, 
associated with near syncope. D. 
Nonsustained ventricular tachycardia 
with continued ST-segment elevation 
associated with palpitations and light-
headedness. 
medscape.com/viewarticle/463306 
USMLE STEP 2  
A 58-year-old African-American male is scheduled to undergo a cardiac 
treadmill stress test in 2 weeks. His family physician recommended the 
test, as the patient would like to begin a new exercise program in order 
to begin training to run a half-marathon later this year. His past medical 
history includes hypertension, which has been well-controlled with 
amlodipine, hyperlipidemia, for which he is taking simvastatin, and non-
insulin dependent diabetes treated with metformin. His history is 
negative for prior myocardial infarction, heart failure, angina, or any 
form of coronary artery disease. Which of the following instructions 
should be given to the patient regarding his upcoming stress test 
1.  Do not consume caffeine or caffeine-containing substances for 5 days 
prior to the stress test  2.  Stop taking aspirin 1 week prior to the stress 
test, 3.  Stop taking amlodipine 2 days prior to the stress test  
4.  Take double the normal dose of metformin and avoid eating the 
morning of the test, 5.  Stop smoking 10 days before the stress test   
USMLE STEP 2   
Correct answer 3:  For patients without a history of coronary artery 
disease, medications including beta-blockers, calcium channel blockers 
(amlodipine), and nitrates should be stopped 48 hours before 
undergoing a cardiac stress test.  
Incorrect Answers: 
1: Caffeine interferes with the results of stress testing; however, it is 
only necessary to withhold consumption for 24 hours before the stress 
test, 2: Aspirin does not affect the quality of the results obtained from 
stress testing, 4: Increasing metformin and skipping a meal may trigger a 
hypoglycemic episode, particularly with the amount of exertion involved 
in an exercise stress test; patients should be instructed to avoid eating 
within 4 hours prior to the test, 5: Although smoking cessation should 
be stressed at every patient encounter, for the purposes of maintaining 
the accuracy of the stress test, cigarette smoking should only be 
stopped for the day of the test.  
Diagnosis 
(Vascular catheterization and angiogram)  
The finger (top left) is pointing to the narrowed 
region of a dye-filled coronary artery. 
atrainceu.com/course-all/coronary-artery-disease-cad-041 
Diagnosis 
(Coronary computed tomography angiography)  
Evaluation of vena saphena graft to right coronary artery. 
Note the permeable graft (double asterisks) and the 
anastomosis with the right coronary artery (single asterisk) 
( A ). 3D reconstruction ( B ).  
.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842016000100026 
Treatment 
(Lifestyle Changes) 
• Salt restriction  
• Moderation of alcohol consumption 
• Other dietary changes (vegetables, low-fat dairy 
products, dietary and soluble fibers, whole 
grains and protein from plant sources, reduced 
in saturated fat and cholesterol) 
• Weight reduction 
• Regular physical exercise 
• Smoking cessation  
 
emedicine.medscape.com/article/198475-overview#a3  
Treatment 
(Education 1) 
• There should be a change in focus in the 
education of all physicians to more strongly 
emphasize evidence based primary 
prevention of SIHD as a part of ASVD  
• Education focused on school children, 
especially targeted to create sustainable 
healthy behavior and sustainable control of 
risk factors  
casinapioiv.va/content/dam/accademia/pdf/atherosclerosis.pdf 
Treatment 
(Education 2) 
• Telemedicine has been proven effective in 
selected world regions 
• Engage the media to promote education for 
SIHD and ASVD  prevention, and the need 
for rapid access to treatment 
• Produce easily accessible (through medical 
journals and internet) guidelines for 
management of IHD and ASVD   
casinapioiv.va/content/dam/accademia/pdf/atherosclerosis.pdf 
Treatment 
(Pharmacotherapy Aims) 
The two aims of the 
pharmacotherapy of 
SIHD patients are to 
obtain relief of 
symptoms and to 
prevent cardiovascular 
(CV) events.   
 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf ehjcimaging.oxfordjournals.org/content/14/8/721 
Treatment 
(Pharmacotherapy Medications 1) 
Medications for risk factors and ischemia 
management:  
• Nitrates,  
• Beta-blockers, 
• Calcium channel blockers, 
•  ivabradine, 
• Nicorandil,  
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Pharmacotherapy Medications 2) 
Medications for risk factors and ischemia 
management:  
• Trimetazidine, 
• Ranolazine, 
• Allopurinol, 
• Molsidomine. 
 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Nitrates 1) 
Short-acting nitrates for acute effort angina: 
• Sublingual nitroglycerin is the standard initial 
therapy for effort angina. When angina starts, the 
patient should rest sitting and take sublingual 
nitroglycerin (0.3–0.6 mg) every 5 min until the pain 
goes or a maximum of 1.2 mg has been taken within 
15 min. Nitroglycerin spray acts more rapidly. 
Nitroglycerin can be used prophylactically when 
angina can be expected, such as activity after a 
meal, emotional stress, sexual activity and in colder 
weather.  
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Nitrates 2) 
Short-acting nitrates for acute effort angina: 
• Isosorbide dinitrate (5 mg sublingually) helps to 
abort anginal attacks for about 1 h.  
Long-acting nitrates (isosorbide dinitrate, 
mononitrates, transdermal nitroglycerin patches) for 
angina prophylaxis are not continuously effective if 
regularly taken over a prolonged period without a 
nitrate-free or nitrate-low interval of about 8–10 
hours (tolerance).  
 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Worsening of endothelial dysfunction is a potential 
complication of long-acting nitrates, hence the 
common practice of the routine use of long-acting 
nitrates as first line therapy for patients with effort 
angina needs re-evaluation.  
Treatment 
(Nitrates 3) 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Beta-blockers) 
Beta-blockers act directly on the heart to reduce 
heart rate, contractility, atrioventricular (AV) 
conduction and ectopic activity.  
Additionally, they may increase perfusion of 
ischaemic areas by prolonging the diastole and 
increasing vascular resistance in non-ischaemic areas.  
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Calcium channel blockers 1) 
• Calcium channel blockers (calcium antagonists) act 
chiefly by vasodilation and reduction of the 
peripheral vascular resistance.  
• Calcium channel blockers can chemically be 
classified into the dihydropyridines and the non- 
dihydropyridines, their common pharmacological 
property being selective inhibition of L-channel 
opening in vascular smooth muscle and in the 
myocardium.  
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Calcium channel blockers 2) 
• The non- dihydropyridines, by virtue of nodal 
inhibition, tend to reduce the heart rate (heart 
rate-lowering agents, verapamil and diltiazem) and 
explain the anti-anginal properties. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Ivabradine) 
• Ivabradine is a heart rate-lowering agent selectively 
inhibiting the sinus node I(f) pacemaking current, 
thereby decreasing the myocardial oxygen demand 
without effect on inotropism/ 
• The effect was predominant in patients with a heart 
rate ≥70 bpm. 
• Ivabradine is an effective anti-anginal agent, alone 
or in combination with b-blockers. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Nicorandil) 
• Nicorandil is a nitrate derivative of nicotinamide 
that can be used for the prevention and long-term 
treatment of angina, and may be added after beta-
blockers and calcium antagonists. 
• Long-term use of oral nicorandil may stabilize 
coronary plaque in patients with stable angina. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Trimetazidine) 
• Trimetazidine is an anti-ischaemic metabolic 
modulator, with similar anti-anginal efficacy to 
propranolol in doses of 20 mg thrice daily.  
• The heart rate and rate × pressure product at rest 
and at peak exercise remained unchanged in the 
trimetazidine group, thus showing a non-
mechanical anti-ischaemic action. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Ranolazine) 
• Ranolazine is a selective inhibitor of late sodium 
current with anti-ischaemic and metabolic 
properties. 
• Ranolazine can be added to other well-established 
anti-anginal drugs, in particular in patients with 
higher HbA1c levels, who may also more often rely 
on medical management. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Allopurinol) 
• Allopurinol, an inhibitor of xanthine oxidase that 
reduces uric acid in persons with gout, is also anti-
anginal.  
• Allopurinol additionally reduced vascular oxidative 
stress. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Molsidomine) 
• This direct NO donor has anti-ischaemic effects 
similar to those of isosorbide dinitrate. 
• The long-acting once-daily 16 mg formulation is as 
effective as 8 mg twice daily. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Pharmacotherapy Medications 2) 
Medications for event prevention:  
• Antiplatelet agents (low-dose aspirin, P2Y12 
inhibitors (thienopyridines) and their 
combinations). 
• Lipid-lowering agents (statins). 
• Renin-angiotensin-aldosterone system blockers. 
 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Antiplatelet Agents) 
• Antiplatelet agents decrease platelet aggregation 
and may prevent formation of coronary thrombus.  
• Due to a favorable ratio between benefit and risk in 
patients with SIHD and its low cost, low-dose aspirin 
is the drug of choice in most cases and clopidogrel 
may be considered for some patients.  
• The use of antiplatelet agents is associated with a 
higher bleeding risk. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Lipid-lowering Agents) 
• Patients with documented CAD are regarded as 
being at very high risk and should be treated with 
statins. 
• The treatment target is LDL-C ,1.8 mmol/L and/or 
more than 50% reduction if the target level cannot 
be reached. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Renin-Angiotensin-Aldosterone System Blockers) 
• Angiotensin converting enzyme (ACE) inhibitors 
reduce total mortality, myocardial infarction, stroke 
and heart failure among specific subgroups of 
patients, including those with heart failure, previous 
vascular disease alone, or high-risk diabetes. 
• Hence, it is appropriate to consider ACE inhibitors 
for the treatment of patients with SIHD, especially 
with co-existing hypertension, left ventricle ejection 
fraction ≤40%, diabetes or chronic kidney disease, 
unless contra-indicated. 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
Treatment 
(Revascularization) 
• Percutaneous coronary 
intervention 
• Coronary artery bypass 
surgery 
• Revascularization vs. 
medical therapy 
eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf emedicine.medscape.com/article/164682-overview 
Prognosis  
• Long-term prognosis in the individual patient is 
unpredictable.  
• There are indications that the course of coronary 
heart disease may be modified, and that the 
pattern of survival may begin to approach that of 
the average population by controlling some of the 
predisposing factors, and by application of such 
measures as dietary restriction of fat and prolonged 
anticoagulation. 
sciencedirect.com/science/article/pii/0002870359901619 
Prophylaxis 1 
• Risk factor assessment and modification should 
begin early in life (childhood) 
• Most risk factors can be modified by lifestyle 
changes as opposed to drug or device treatment 
• Solidarity in primary prevention efforts will benefit 
both the individual and the society as a whole 
• Effective treatment reduces the first clinical 
manifestations of SIHD and ASVD    
casinapioiv.va/content/dam/accademia/pdf/atherosclerosis.pdf 
Prophylaxis 2 
• The role of Governments is crucial   
• Aggregate risk factor reduction can decrease 
cardiovascular events by as much as 70% 
• Adequate Secondary prevention measures can 
reduce vascular event recurrence by 75% 
casinapioiv.va/content/dam/accademia/pdf/atherosclerosis.pdf 
Abbreviations  
• ACE - angiotensin converting 
enzyme 
• ASVD – atherosclerotic 
vascular disease  
• CT – computer tomography 
• CV - cardiovascular 
• CAD -coronary artery disease 
• ECG – electrocardiography 
• ICD - International 
Classification of Diseases 
 
 
• IGT - impaired glucose 
tolerance  
• IHD - ischemic heart disease 
• HDL – high-density lipoprotein 
• LDL - low-density lipoprotein  
• MRA –  magnetic resonance 
angiogram 
• miRNAs - posttranscriptional 
regulators    
• SIHD – stable forms of  
ischemic heart disease 
 
 
Diagnostic and treatment guidelines 
• 2017 Focused update on Dual Antiplatelet Therapy (DAPT) 
• 2016 ACC/AHA Guideline Focused Update on Duration of 
Dual Antiplatelet Therapy in Patients With Coronary Artery 
Disease 
• Joint 2016 European Guidelines on Cardiovascular Disease 
Prevention in Clinical  
• Practice2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused 
Update of the Guideline for the Diagnosis and Management 
of Patients With Stable Ischemic Heart Disease 
• 2013 ESC guidelines on the management of stable coronary 
artery disease  
•  
 
 
 
 
 
